Transaction DateRecipientSharesTypePriceValue
17th November 2020Daniel N Jr Swisher10,000Open or private sale$6.25$62,505.00
17th November 2020Daniel N Jr Swisher10,000Exercise of derivative$2.90$29,000.00
19th October 2020Daniel N Jr Swisher5,000Exercise of derivative$6.55$32,750.00
19th October 2020Daniel N Jr Swisher5,000Open or private sale$17.66$88,301.00
13th October 2020Eric Bjerkholt23,905Sale back to the issuer$34.50$824,722.50
10th October 2020Eric Bjerkholt27,805Disposition due to a tender of shares in a change of control transaction$34.50$959,272.50
5th October 2020Eric Bjerkholt4,281Exercise of derivative$0.00
5th October 2020Eric Bjerkholt5,200Exercise of derivative$19.44$101,088.00
15th September 2020Eric Bjerkholt840Payment by withholding$34.25$28,770.00
5th September 2020Timothy L. Moore4,296Exercise of derivative$0.00
Cerus
Cerus logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The company produces blood system for platelets and plasma. It markets products under the INTERCEPT brand.


Ticker: CERS
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1020214
Employees: 254
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $35 M (0%)
Inventory, Net: $18 M (0%)
Assets, Current: $179 M (39%)
Property, Plant and Equipment, Net: $15 M (-2%)
Other Assets, Noncurrent: $4 M (-2%)
Assets: $215 M (30%)
Accounts Payable, Current: $19 M (-15%)
Accrued Liabilities, Current: $17 M (0%)
Liabilities, Current: $43 M (-14%)
Other Liabilities, Noncurrent: $713 Th (118%)
Liabilities: $101 M (-6%)
Common Stock, Value, Issued: $166 Th (15%)
Additional Paid in Capital, Common Stock: $995 M (9%)
Retained Earnings (Accumulated Deficit): $881 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (886%)
Stockholders' Equity (Parent): $115 M (0%)
Liabilities and Equity: $215 M (30%)
Cost of Revenue: $10 M (-46%)
Operating Income/Loss: $15 M (-51%)
Other Income, net: $196 Th (-83%)
Provision for income taxes: $67 Th (-45%)